EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Feb 25, 2021
|
EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Feb 25, 2021
|
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
Feb 04, 2021
|
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Feb 01, 2021
|
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Feb 01, 2021
|
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
Jan 28, 2021
|
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
Jan 11, 2021
|
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
Jan 03, 2021
|
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation
Dec 18, 2020
|
EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Dec 08, 2020
|
EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
Dec 03, 2020
|
EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
Nov 19, 2020
|
EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
Nov 16, 2020
|
EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
Nov 10, 2020
|
EyePoint Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Nov 05, 2020
|
EyePoint Pharmaceuticals Announces Third Quarter 2020 Financial Results Release Date and Conference Call Information
Oct 29, 2020
|
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
Oct 08, 2020
|
EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020
Oct 07, 2020
|
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Sep 10, 2020
|
EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
Aug 24, 2020
|